A clinical trial update dated June 5, 2026 confirms the status of a study involving exenatide, an approved GLP-1 analogue. The trial, titled "GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)," is registered under identifier NCT05356104. According to the listing, the study is in Phase 2 and its current status is recruiting.
The trial's title indicates it is examining a GLP-1 analogue in relation to small vessel disease progression, but no outcome data, efficacy findings, or safety results have been reported as part of this update. The information available reflects only the trial's registration status, phase, and recruitment stage as of the update date.
No results have been posted for this study at this time. This brief reflects only the recruiting status noted in the trial record and does not indicate any conclusions about the compound's effects. Readers interested in the study can consult the official trial registry for further details on eligibility and design.
For more background on exenatide, including its approved uses and general profile, see the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05356104"]